Page last updated: 2024-12-07

firefly luciferin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Firefly luciferin is a chemical compound that is responsible for the bioluminescence of fireflies. It is a benzothiazole derivative that undergoes oxidation in the presence of oxygen and the enzyme luciferase to produce light. This reaction is highly efficient, with almost 100% of the energy released as light. Firefly luciferin is synthesized in the firefly's body from cysteine and adenosine triphosphate (ATP). The luciferin is stored in specialized cells called photocytes, which are located in the firefly's abdomen. When a firefly flashes, it releases luciferin into the photocytes, where it reacts with oxygen and luciferase to produce light. The color of the light emitted by a firefly is determined by the structure of the luciferin molecule. Firefly luciferin has a number of interesting properties. It is highly sensitive to oxygen, making it a useful tool for measuring oxygen levels. It is also very stable, which makes it suitable for use in a variety of applications. Firefly luciferin is used in a variety of research applications, including the study of bioluminescence, enzyme kinetics, and cellular signaling. It is also used in diagnostic and imaging applications, such as the detection of cancer cells. The study of firefly luciferin and its related enzymes is important for understanding the mechanisms of bioluminescence and for developing new applications for this technology. Firefly luciferin is a fascinating and useful molecule with a wide range of applications.'

Firefly Luciferin: A benzothaizole which is oxidized by LUCIFERASES, FIREFLY to cause emission of light (LUMINESCENCE). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Photinus luciferin : A 1,3-thiazolemonocarboxylic acid consisting of 3,5-dihydrothiophene-4-carboxylic acid having a 6-hydroxybenzothiazol-2-yl group at the 2-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID92934
CHEMBL ID443738
CHEBI ID17165
SCHEMBL ID565455
SCHEMBL ID49401
MeSH IDM0464579

Synonyms (56)

Synonym
CHEBI:17165 ,
(s)-4,5-dihydro-2-(6-hydroxybenzothiazol-2-yl)thiazole-4-carboxylic acid
(4s)-2-(6-hydroxy-1,3-benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid
luciferin ,
C02740
(s)-4,5-dihydro-2-(6-hydroxy-1,3-benzothiazol-2-yl)thiazole-4-carboxylic acid
firefly luciferin
(s)-4,5-dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid
photinus luciferin
2591-17-5
d-luciferin, synthetic, bioxtra, >=99% (hplc)
d-luciferin, synthetic
L-8200
d-luciferin firefly
d-(-)-luciferin
(s)-2-(6-hydroxy-2-benzothiazolyl)-2-thiazoline-4-carboxylic acid
d-luciferin ,
CHEMBL443738 ,
A818071
(s)-2-(6-hydroxybenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid ,
einecs 219-981-3
unii-5tbb02n29k
4-thiazolecarboxylic acid, 4,5-dihydro-2-(6-hydroxy-2-benzothiazolyl)-, (s)-
5tbb02n29k ,
AKOS015916008
S7763
SCHEMBL565455
TD8085
bdbm50440036
SCHEMBL49401
(4s)-4,5-dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid
firefly luciferin [mi]
CS-4970
d-luciferin, potassium salt
4-thiazolecarboxylic acid, 4,5-dihydro-2-(6-hydroxy-2-benzothiazolyl)-, (4s)-
BJGNCJDXODQBOB-SSDOTTSWSA-N
HY-12591A
mfcd00042929
EX-A617
AC-8545
d(-)-luciferin, d(-)-2-(6'-hydroxy-benzothiazolyl)d2-thiazoline-4-carboxylic acid from photinus pyralis, synthetic
AS-54711
IWJYWBVPCGUPLO-BFUDMSGGSA-N
DTXSID00894865
Q3265801
firefly luciferin (ketone tautomer)
Q63390514
d-luciferin free acid
(4s)-2-(6-hydroxy-1,3-benzothiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid
AMY5413
CCG-267246
d-luciferin,freeacid
AKOS037644789
EN300-99574
d-luciferin, free acid
PD087236

Research Excerpts

Overview

Firefly luciferin is a natural product that is well-known to function as the substrate of the bioluminescence reaction in luminous beetles. It is restricted to fireflies (family Lampyridae) and other select families of beetles (order Coleoptera)

ExcerptReferenceRelevance
"Firefly luciferin is a natural product that is well-known to function as the substrate of the bioluminescence reaction in luminous beetles. "( 2-S-cysteinylhydroquinone is an intermediate for the firefly luciferin biosynthesis that occurs in the pupal stage of the Japanese firefly, Luciola lateralis.
Kanie, S; Nakai, R; Oba, Y; Ojika, M, 2018
)
2.17
"Firefly luciferin is a specialized metabolite restricted to fireflies (family Lampyridae) and other select families of beetles (order Coleoptera). "( Sulfoluciferin is Biosynthesized by a Specialized Luciferin Sulfotransferase in Fireflies.
Fallon, TR; Li, FS; Vicent, MA; Weng, JK, 2016
)
1.88

Effects

ExcerptReferenceRelevance
"Firefly luciferin system probes have been successfully applied for analyzing physiological processes, monitoring the environment, diagnosing diseases, screening candidate drugs, and evaluating the therapeutic effect."( Constructing firefly luciferin bioluminescence probes for
Du, L; Ji, H; Li, M; Qin, X; Yang, X, 2022
)
1.81

Toxicity

ExcerptReferenceRelevance
" AFB was selective toxic towards the human hepatocytes and relatively noncytotoxic towards 3T3 cells both in the presence and absence of the hepatocytes."( Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclo
LaForge, YS; Li, AP; Uzgare, A, 2012
)
0.38
" The method was successfully employed in the toxic effect test of NaF, NaCl, KBr and NaBF4 on luciferase."( [Microplate luminometry for toxicity bioassay of chemicals on luciferase].
Chen, F; Ge, HL; Liu, SS; Lü, DZ; Luo, JH; Su, BX, 2013
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
" Here, we present a novel pharmacokinetic (PK) approach that utilizes bioluminescence image data."( Pharmacokinetic modeling of tumor bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapy.
Bibee, K; Sept, D; Sim, H; Wickline, S, 2011
)
0.37
" Herein, the intracellular pharmacokinetic behavior of D-luciferin was investigated in pancreatic cancer cell lines in real time by using bioluminescence imaging."( Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells.
Gu, M; Li, F; Liu, J; Sun, Y; Wei, Y; Xiong, Y; Zhu, L, 2016
)
0.43
" To address this problem, we designed a pharmacokinetic (PK) model which is suitable for applying on IV administration of small amounts of D-Luciferin."( Intravenous Administration-Oriented Pharmacokinetic Model for Dynamic Bioluminescence Imaging.
Chen, D; Chen, X; Dai, Y; Liang, J; Nie, Y; Wang, G; Wu, K; Yin, J; Zhan, Y, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" Additionally, US mediated microbubble delivery of p53 and RB combined with external beam radiation resulted in the most profound tumor reduction in DU-145 xenografted nude mice (p<0."( Microbubble-assisted p53, RB, and p130 gene transfer in combination with radiation therapy in prostate cancer.
Brunetti, A; Claudio, L; Claudio, PP; Denvir, J; Gossman, MS; Greco, A; Howard, CM; Lopez, JP; Nande, R; Salvatore, M, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" Molecular transporter conjugates of otherwise poorly soluble or poorly bioavailable drugs or probes exhibit excellent solubility in water and biological fluids and at the same time an enhanced ability to enter tissues and cells and with modification to do so selectively."( Real-time analysis of uptake and bioactivatable cleavage of luciferin-transporter conjugates in transgenic reporter mice.
Contag, CH; Goun, EA; Jones, LR; Pillow, TH; Rothbard, JB; Shinde, R; Wender, PA, 2007
)
0.34
" Since there are few studies on in vivo monitoring of drug delivery dynamics, the time course or bioavailability of drugs in the inner ear of live animals following systemic drug application remains unknown."( Novel in vivo imaging analysis of an inner ear drug delivery system: Drug availability in inner ear following different dose of systemic drug injections.
Fujioka, M; Kanzaki, S; Nakamura, M; Ogawa, K; Okano, H; Okano, HJ; Shibata, S; Watanabe, K, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" Such investigations from the object of the present work in which there is proved that the microanalytical method for the dosing of ATP, based on the enzymatic reaction with luciferin-luciferase system, may be converted into a ultramicroanalytical method and therefore used also in other fields of research, as for example the ATP biosynthesis in cell cultures."( Contributions to the perfecting of the enzymatic method used for the determination of ATP in biological systems.
Trutia, E; Vasilescu, V; Zaciu, C, 1975
)
0.25
" The dose-response data correlated well with target cell viable count."( Real-time measurement of cell permeabilization with low-molecular-weight membranolytic agents.
Akerman, KE; Karp, MT; Oker-Blom, C; Saviranta, P; Virta, M, 1995
)
0.29
" Luciferin dosage was a critical determinant of the magnitude of photon emission from these reporter mice."( Bioluminescent detection of endotoxin effects on HIV-1 LTR-driven transcription in vivo.
Blackwell, TS; Christman, JW; Everhart, MB; Han, W; Jansen, ED; Sadikot, RT; Yull, FE, 2003
)
0.32
" Stable bioluminescent cell lines have been established and they provide reproducible dose-response curves and accurate determination of in vitro efficiencies of various chemicals."( In vivo bioluminescence imaging to evaluate estrogenic activities of endocrine disrupters.
Balaguer, P; Nicolas, JC; Pillon, A; Servant, N; Vignon, F, 2005
)
0.33
" Further studies will show whether a high dosage of drug is effective or not."( Novel in vivo imaging analysis of an inner ear drug delivery system: Drug availability in inner ear following different dose of systemic drug injections.
Fujioka, M; Kanzaki, S; Nakamura, M; Ogawa, K; Okano, H; Okano, HJ; Shibata, S; Watanabe, K, 2015
)
0.42
" In addition, gemcitabine increased the elimination rate of the ABCG2 substrate, D-luciferin, and decreased D-luciferin accumulation in BxPC3 and Panc1 cells in a dose-response manner."( Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells.
Gu, M; Li, F; Liu, J; Sun, Y; Wei, Y; Xiong, Y; Zhu, L, 2016
)
0.43
" Upon treatment of CHIM with the estimated lumen concentration of the HS upon each oral administration (manufacturers' recommended dosage dissolved in 200 ml of culture medium), >80% CYP3A inhibition was observed for green tea extract, St."( Application of Cryopreserved Human Intestinal Mucosa and Cryopreserved Human Enterocytes in the Evaluation of Herb-Drug Interactions: Evaluation of CYP3A Inhibitory Potential of Grapefruit Juice and Commercial Formulations of Twenty-Nine Herbal Supplement
Alam, N; Ho, MD; Li, AP; Loretz, C; Mitchell, W, 2020
)
0.56
" At standard doses, Antares-CFz matches AkaLuc-AkaLumine/TokeOni in brightness, while occasional higher dosing of CFz can be performed to obtain threefold more signal."( An optimized bioluminescent substrate for non-invasive imaging in the brain.
Casey, KM; Encell, LP; Hall, MP; Hong, G; Kirkland, TA; Klein, MA; Lin, MZ; Liu, LX; Su, Y; Walker, JR; Wu, X, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
luciferinA low-molecular-mass compound present in bioluminescent organisms that emits light when oxidized in presence of enzyme luciferase.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzothiazoles
1,3-thiazolemonocarboxylic acid
imidothioateA compound with the general formula R'-N=C(SR)R'' where R is organyl and R' and R'' can be organyl or H.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 35Homo sapiens (human)Ki9.86000.01152.44679.8600AID769725
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 35Homo sapiens (human)EC50 (µMol)144.95000.00202.50079.8000AID769735; AID769737
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
cytoskeleton organizationG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationG-protein coupled receptor 35Homo sapiens (human)
chemokine-mediated signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityG-protein coupled receptor 35Homo sapiens (human)
negative regulation of neuronal action potentialG-protein coupled receptor 35Homo sapiens (human)
positive regulation of Rho protein signal transductionG-protein coupled receptor 35Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor activityG-protein coupled receptor 35Homo sapiens (human)
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (121)

Assay IDTitleYearJournalArticle
AID1205430Inhibition of PKC-zeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205372Inhibition of HER4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID769725Displacement of [3H]PSB-13253 from human recombinant GPR35 exprssed in CHO cells by liquid scintillation counting analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
AID1205404Inhibition of IKKbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205420Inhibition of YES1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205444Inhibition of p38alpha MAPK(unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205379Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205367Inhibition of GCK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1481450Drug uptake in HEK293T cells expressing luciferase reporter gene at 6.3 uM measured every 3 mins for 60 mins by luminescence assay relative to 50 uM luciferin2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1205428Inhibition of NEK6 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205415Inhibition of CK1delta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205409Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1481458Drug uptake in HEK293T cells expressing luciferase reporter gene at 1.9 uM measured every 3 mins for 60 mins by luminescence assay relative to 50 uM luciferin2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1205398Inhibition of PHK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205431Inhibition of ERK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205382Inhibition of Aurora B (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205360Inhibition of N-terminal His-tagged CDK2-cyclin A (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205439Inhibition of MEKK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205429Inhibition of EPH-B3 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID102511Michaelis-Menten constant for binding affinity towards firefly luciferase2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis of 7'-[123I]iodo-D-luciferin for in vivo studies of firefly luciferase gene expression.
AID1205418Inhibition of MAPKAPK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205347Inhibition of DYRK3 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205437Inhibition of p38gamma MAPK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205393Inhibition of AMPK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205421Inhibition of PAK5 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205433Inhibition of PAK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205365Inhibition of CAMK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205434Inhibition of CSK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205424Inhibition of p38beta MAPK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1481463Cytotoxicity against HEK293T cells assessed as cell viability at 16.7 uM by CellTiter-Glo assay relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1205414Inhibition of EF2K (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205351Inhibition of IRR (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205432Inhibition of SYK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205400Inhibition of NEK2a (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205344Binding affinity to N-terminal His-tagged CDK2 (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as melting temperature by thermal shift assay (Rvb = 41.5 degC)2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205390Inhibition of CAMKK-beta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1481455Cytotoxicity against HEK293T cells assessed as cell viability at 12.5 uM by CellTiter-Glo assay relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1205405Inhibition of RSK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205442Inhibition of LCK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205387Inhibition of PRAK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205348Inhibition of PIM3 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205358Inhibition of MNK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205354Inhibition of PIM1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205410Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205373Inhibition of S6K1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205350Inhibition of CK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1481451Drug uptake in HEK293T cells expressing luciferase reporter gene at 12.5 uM measured every 3 mins for 60 mins by luminescence assay relative to 50 uM luciferin2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1205359Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205357Inhibition of TrkA (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205425Inhibition of IR (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205426Inhibition of p38delta MAPK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205407Inhibition of MST4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID769735Agonist activity at human GPR35 expressed in human HT29 cells by DMR assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
AID1205380Inhibition of TTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1481454Cytotoxicity against HEK293T cells assessed as cell viability at 6.3 uM by CellTiter-Glo assay relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1205446Inhibition of EPH-A4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205375Inhibition of CHK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205441Inhibition of JNK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205371Inhibition of PIM2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205416Inhibition of JAK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205411Inhibition of PKCalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205401Inhibition of MARK3 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205419Inhibition of PKA (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205402Inhibition of PRK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205445Inhibition of Src (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205362Inhibition of NUAK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205383Inhibition of HIPK3 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205386Inhibition of SRPK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205396Inhibition of PAK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205391Inhibition of MLK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1481452Drug uptake in HEK293T cells expressing luciferase reporter gene at 25 uM measured every 3 mins for 60 mins by luminescence assay relative to 50 uM luciferin2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1481459Drug uptake in HEK293T cells expressing luciferase reporter gene at 5.6 uM measured every 3 mins for 60 mins by luminescence assay relative to 50 uM luciferin2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1205395Inhibition of EPH-A2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205413Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205364Inhibition of RSK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205361Inhibition of GSK-3beta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205427Inhibition of ERK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1481461Cytotoxicity against HEK293T cells assessed as cell viability at 1.9 uM by CellTiter-Glo assay relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1205397Inhibition of FGF-R1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205370Inhibition of MLK3 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205355Inhibition of VEGFR (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205403Inhibition of IRAK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205394Inhibition of TAK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205389Inhibition of IGF-1R (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1481462Cytotoxicity against HEK293T cells assessed as cell viability at 5.6 uM by CellTiter-Glo assay relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1205423Inhibition of JNK3 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID769737Agonist activity at human GPR35 expressed in HT29 cells by beta-arrestin translocation assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
AID1205349Inhibition of ERK8 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205438Inhibition of EPH-B4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205376Inhibition of BRSK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205392Inhibition of PKD1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1481456Cytotoxicity against HEK293T cells assessed as cell viability at 25 uM by CellTiter-Glo assay relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1205435Inhibition of PAK6 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205374Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205384Inhibition of MSK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID769724Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells at 10 uM after 90 mins by beta-arrestin recruitment assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
AID1205352Inhibition of MAPKAPK3 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205443Inhibition of CHK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205385Inhibition of SmMLCK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205417Inhibition of MARK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205377Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205408Inhibition of PLK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205422Inhibition of MARK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205378Inhibition of Aurora A (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205353Inhibition of MNK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205369Inhibition of RIPK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205412Inhibition of MST2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205381Inhibition of LKB1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205363Inhibition of MINK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205368Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205399Inhibition of HIPK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205366Inhibition of BRSK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205440Inhibition of PDK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205356Inhibition of HIPK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205346Inhibition of DYRK1A (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205406Inhibition of MKK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1481457Cytotoxicity against HEK293T cells assessed as cell viability at 50 uM by CellTiter-Glo assay relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1481460Drug uptake in HEK293T cells expressing luciferase reporter gene at 16.7 uM measured every 3 mins for 60 mins by luminescence assay relative to 50 uM luciferin2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.
AID1205388Inhibition of SGK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205345Inhibition of DYRK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
AID1205436Inhibition of JNK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (930)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990330 (35.48)18.7374
1990's94 (10.11)18.2507
2000's176 (18.92)29.6817
2010's265 (28.49)24.3611
2020's65 (6.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.45 (24.57)
Research Supply Index6.90 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index73.19 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews72 (7.28%)6.00%
Case Studies3 (0.30%)4.05%
Observational0 (0.00%)0.25%
Other914 (92.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]